CD274 and non-small cell lung carcinoma: Indeed, the author’s own clinical trial (NCT04895579) attempts to address “the low or no benefit reality” non-small cell lung cancer get from single agent PD-L1 inhibitor durvalumab consolidation after concurrent chemoradiation therapy if their cancer express low or no PD-L1.